Vertex Pharmaceuticals Inc (VRTX) 92.85 $VRTX
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
Market Activity, Drug Approval, Upcoming Conference, and Presentation of Clinical Data - Research Reports on Jazz, Keryx, Vertex, WellPoint and GSK
PR Newswire - Wed Sep 10, 8:15AM CDT
Today, Analysts Review released its research reports regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Keryx Biopharmaceuticals (NASDAQ: KERX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), WellPoint Inc. (NYSE: WLP) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6356-100free.
Stock Market News for September 08, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:10AM CDT
Benchmarks ended in the green on Friday as a dismal job report reduced fears among investors about sooner-than-expected rate hike
Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
Business Wire - Mon Sep 08, 8:01AM CDT
---Other presentations include studies of ivacaftor in people with cystic fibrosis who have the R117H mutation, in people with residual function mutations and in children ages 2 to 5-
Vertex Pharmaceuticals Rises 3.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Sep 05, 3:55PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.55 to a high of $96.31. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $94.30 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.81% Yesterday
Comtex SmarTrend(R) - Fri Sep 05, 3:54PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.55 to a high of $96.31. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $94.30 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upgrade Alert for Vertex Pharmaceuticals (VRTX)
Comtex SmarTrend(R) - Fri Sep 05, 6:59AM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $91.55 on volume of 864,000 shares, below average daily volume of 1.3 million. There is potential upside of 17.1% for shares of Vertex Pharmaceuticals based on a current price of $91.55 and an average consensus analyst price target of $107.24. The stock should hit resistance at its 50-day moving average (MA) of $92.94, as well as support at its 200-day MA of $77.84.
Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
Business Wire - Tue Sep 02, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10 at 8:35 a.m. ET.
Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials
GlobeNewswire - Tue Sep 02, 7:30AM CDT
Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the expansion of its drug development team with three strategic hires to support upcoming studies for its lead product candidate, NS2.
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 28, 7:00PM CDT
Gilead Sciences ' hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as you'd expect, total...
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 26, 3:58PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.89 to a high of $94.50. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $92.55 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Vertex Pharmaceuticals Rises 2.05% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 3:58PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.89 to a high of $94.50. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $92.55 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
After Yesterday's Decline of 2.53%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Aug 21, 4:29PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.38 to a high of $91.88. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $90.57 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 2.53% Sell Off
Comtex SmarTrend(R) - Thu Aug 21, 4:29PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.38 to a high of $91.88. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $90.57 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Vertex Pharmaceuticals Earnings Review: 20 Days after Announcement Shares Down 4.9% (VRTX)
Comtex SmarTrend(R) - Mon Aug 18, 10:17AM CDT
When Vertex Pharmaceuticals (NASDAQ:VRTX) reported earnings 20 days ago on July 29th, 2014, analysts, on average, expected the company to report a loss of $0.55 on sales of $131.1 million. The company actually reported a loss of $0.61 per share on sales of $138.4 million, missing EPS estimates by $0.06 and beating revenue estimates by $7.4 million. Since the company's report, shares of Vertex Pharmaceuticals have fallen from $95.56 to $90.88, representing a loss of 4.9% in the past 20 days.
Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.
Analyst Scanner on Biotech Equities - Prana Biotechnology, CytRx, Insmed, Dynavax Technologies, and Vertex Pharma
PR Newswire - Thu Sep 11, 8:15AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Health Care Sector Index ended the day at 744.25, up 0.67%, with the index gaining 7.42% in the previous three months. Investor-Edge has initiated coverage on the following equities: Prana Biotechnology Ltd (NASDAQ: PRAN), CytRx Corporation (NASDAQ: CYTR), Insmed Inc. (NASDAQ: INSM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free research on these five companies can be accessed at:
Market Activity, Drug Approval, Upcoming Conference, and Presentation of Clinical Data - Research Reports on Jazz, Keryx, Vertex, WellPoint and GSK
PR Newswire - Wed Sep 10, 8:15AM CDT
Today, Analysts Review released its research reports regarding Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Keryx Biopharmaceuticals (NASDAQ: KERX), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), WellPoint Inc. (NYSE: WLP) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6356-100free.
Stock Market News for September 08, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:10AM CDT
Benchmarks ended in the green on Friday as a dismal job report reduced fears among investors about sooner-than-expected rate hike
Vertex Announces Upcoming Presentations of Data at North American Cystic Fibrosis Conference - October 9 to 11, 2014
Business Wire - Mon Sep 08, 8:01AM CDT
---Other presentations include studies of ivacaftor in people with cystic fibrosis who have the R117H mutation, in people with residual function mutations and in children ages 2 to 5-
Vertex Pharmaceuticals Rises 3.81% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Sep 05, 3:55PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.55 to a high of $96.31. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $94.30 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.81% Yesterday
Comtex SmarTrend(R) - Fri Sep 05, 3:54PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $93.55 to a high of $96.31. Yesterday, the shares gained 3.8%, which took the trading range above the 3-day high of $94.30 on volume of 2.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upgrade Alert for Vertex Pharmaceuticals (VRTX)
Comtex SmarTrend(R) - Fri Sep 05, 6:59AM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) was upgraded from Neutral to Buy at Goldman Sachs today. The stock closed yesterday at $91.55 on volume of 864,000 shares, below average daily volume of 1.3 million. There is potential upside of 17.1% for shares of Vertex Pharmaceuticals based on a current price of $91.55 and an average consensus analyst price target of $107.24. The stock should hit resistance at its 50-day moving average (MA) of $92.94, as well as support at its 200-day MA of $77.84.
Vertex to Present at the Morgan Stanley Global Healthcare Conference on September 10
Business Wire - Tue Sep 02, 3:01PM CDT
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 10 at 8:35 a.m. ET.
Aldeyra Therapeutics Expands Drug Development Team in Advance of NS2 Clinical Trials
GlobeNewswire - Tue Sep 02, 7:30AM CDT
Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced the expansion of its drug development team with three strategic hires to support upcoming studies for its lead product candidate, NS2.
Upcoming Conferences, Market Activity, Drug Approval, and Earnings Release - Research Reports on Mallinckrodt, Vertex Pharmaceuticals, Kite, Bristol-Myers Squibb and Arrowhead
PR Newswire - Fri Aug 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Mallinckrodt plc (NYSE: MNK), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), Kite Pharma, Inc. (NASDAQ: KITE), Bristol-Myers Squibb Company (NYSE: BMY) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6071-100free.
Has Gilead Sciences, Inc.'s Star Drug Already Peaked?
Brian Orelli, The Motley Fool - Motley Fool - Thu Aug 28, 7:00PM CDT
Gilead Sciences ' hepatitis C drug scored $3.5 billion in sales in the second quarter, but prescriptions have been falling since before the quarter closed. First, new prescriptions started to fall in March. And then, as you'd expect, total...
After Yesterday's Rally of 2.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Aug 26, 3:58PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.89 to a high of $94.50. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $92.55 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Vertex Pharmaceuticals Rises 2.05% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Aug 26, 3:58PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $90.89 to a high of $94.50. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high of $92.55 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stock Market News for August 26, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Aug 26, 9:10AM CDT
The S&P 500 closed at a record high and fellow benchmarks also ended in the green boosted by deal news
After Yesterday's Decline of 2.53%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Thu Aug 21, 4:29PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.38 to a high of $91.88. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $90.57 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Look for Shares of Vertex Pharmaceuticals to Potentially Rebound after Yesterday's 2.53% Sell Off
Comtex SmarTrend(R) - Thu Aug 21, 4:29PM CDT
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $88.38 to a high of $91.88. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $90.57 on volume of 1.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
Vertex Pharmaceuticals Earnings Review: 20 Days after Announcement Shares Down 4.9% (VRTX)
Comtex SmarTrend(R) - Mon Aug 18, 10:17AM CDT
When Vertex Pharmaceuticals (NASDAQ:VRTX) reported earnings 20 days ago on July 29th, 2014, analysts, on average, expected the company to report a loss of $0.55 on sales of $131.1 million. The company actually reported a loss of $0.61 per share on sales of $138.4 million, missing EPS estimates by $0.06 and beating revenue estimates by $7.4 million. Since the company's report, shares of Vertex Pharmaceuticals have fallen from $95.56 to $90.88, representing a loss of 4.9% in the past 20 days.
Biotech, Social Media Stocks Are Less Frothy Than Janet Yellen Thinks
at The Street - Thu Aug 14, 11:34AM CDT
A month after Fed Chair Janet Yellen's comments, ETFs covering both groups are pushing towards new highs on strong fundamental backdrops.
